Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834976 | 0.90 | CA2 (0.38) | CA2 | |
| SCHEMBL8687335 | 0.89 | CA2 (0.37) | CA2 | |
| SCHEMBL8914984 | 0.83 | — | — | |
| SCHEMBL8914514 | 0.75 | MAP2K7 (0.30) | CDC25ACDC25B | |
| SCHEMBL8917405 | 0.75 | MAP2K7 (0.30) | CDC25ACDC25B | |
| SCHEMBL2158372 | 0.74 | — | — | |
| SCHEMBL8914385 | 0.73 | POLB (0.42) | — | |
| SCHEMBL6865366 | 0.69 | TSHR (0.39) | — | |
| SCHEMBL6839095 | 0.66 | IDO1 (0.34) | — | |
| SCHEMBL8915228 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806371-B2 | BY MEANS OF PHASE TRANSFER CATALYSIS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2004-10-19 | — | — | US | disclosed |
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-01 | — | — | US | disclosed |
| US-6162809-A | Pyridylthio compounds for controlling helicobacter bacteria | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| US-5922720-A | PHARMACEUTICAL FOR USE IN TREATMENT OF DISEASES BASED ON HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| US-5859030-A | Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-01-12 | — | — | US | disclosed |
| US-5773451-A | BACTERICIDES FOR HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063957-A1 | Preparation of substituted pyridine N-oxide compounds | HRH2, SCO2, CBR1 | CA2 402/4885S100A4 3456/4885CDC25A 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.